Answers are grounded in this paper and cite their sources.
Demonstrates beta-adrenoceptor blockade with intrinsic sympathomimetic and membrane stabilizing activity across animal models, highlighting the active pharmacology of this propranolol metabolite.
4-Hydroxypropranolol, a metabolite produced after oral administration of propranolol, has been shown to be a beta-adrenoceptor blocking drug. It is of similar potency to propranolol in antagonizing the effects of isoprenaline on heart rate and blood pressure in cats and against isoprenaline protection of guinea-pigs from bronchospasm. It is not cardioselective.2. In rats depleted of catecholamine 4-hydroxypropranolol produced an increase in heart rate, suggesting that it has intrinsic sympathomimetic activity.3. In anaesthetized dogs 4-hydroxypropranolol produced a decrease in heart rate and dP/dt and an increase in A-V conduction time at doses within the range 0.09-1.25 mg/kg. These effects are a result of beta-adrenoceptor blockade. In dogs depleted of catecholamines these same doses produced an increase in heart rate and dP/dt and a decrease in A-V conduction time. These responses were antagonized by propranolol, and were due to the intrinsic sympathomimetic activity of the compound. At higher doses (5.25 and 13.25 mg/kg) a further dose dependent decrease in heart rate and dP/dt and an increase in A-V conduction time occurred. This trend was also seen in animals depleted of catecholamines. These changes represent membrane stabilizing activity of 4-hydroxypropranolol.4. 4-Hydroxypropranolol is a potent beta-adrenoceptor blocking drug with both intrinsic sympathomimetic activity and membrane stabilizing activity.
No takes yet. Share an insight, caveat, or question.
Fitzgerald et al. (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: